Skip to content
Screener

AOCI at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
-$13.95B+2.5%
Hims & Hers Health logo
Hims & Hers HealthHIMS
-$4.41M-2,586%
Organon logo
OrganonOGN
-$539M+12.6%
PVL
Palvella TherapeuticsPVLA
$95K+3,267%
PTH
Pelthos TherapeuticsPTHS
$3.19M
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
-$1.62M-516%

Other financials

Income statement

See full
Operating income-$29.9M-131%
Net income-$27.2M-120%
EPS (diluted)-$1.32+93.3%

Balance sheet

See full
Cash & equivalents$168.4M+419%
Total debt$4.0K
Total equity$390.6M+744%
Total assets$397.4M

Cash flow

See full
Operating cash flow-$21.2M-59.0%
CapEx--100%
Free cash flow-$21.2M-58.7%

Valuation

See full
Market cap$4.65B+269%

Returns & leverage

See full
Return on equity-28.7%
Current ratio59.1×

Where this comes from

Reported directly by Veradermics in its filing.

Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.

The source filing: Veradermics’s 10-Q, filed May 12, 2026. Open the filing →

Filed
May 12, 2026, 5:06 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001827635-26-000019

FAQ

What is Veradermics's AOCI?
Veradermics (MANE) reported AOCI of -$524K in Q1 2026.
What does AOCI mean?
Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.

Ask your AI about Veradermics's aoci.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude